Compare SPRY & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRY | GSBD |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2020 | 2013 |
| Metric | SPRY | GSBD |
|---|---|---|
| Price | $9.11 | $9.37 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | $9.00 |
| AVG Volume (30 Days) | 889.4K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.76% |
| EPS Growth | ★ 114.04 | 87.27 |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $89,149,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.97 | N/A |
| P/E Ratio | ★ N/A | $9.05 |
| Revenue Growth | ★ 297063.34 | N/A |
| 52 Week Low | $6.66 | $8.81 |
| 52 Week High | $18.63 | $12.43 |
| Indicator | SPRY | GSBD |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 53.25 |
| Support Level | $8.61 | $8.99 |
| Resistance Level | $10.44 | $9.55 |
| Average True Range (ATR) | 0.44 | 0.23 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 40.31 | 77.21 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.